Sakar Healthcare delivered exceptional financial performance in the June 2026 quarter, with consolidated net profit surging 120.13% to ₹10.28 crore compared to ₹4.67 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a remarkable turnaround in the company's profitability metrics during the first quarter of fiscal 2026. The company's PAT margin expanded to 14% from 9% year-on-year, supported by operating leverage, improved efficiencies, and disciplined cost management.
The company's sales revenue increased by 38.36% to ₹72.97 crore in Q1 FY2026, up from ₹52.74 crore in the same period last year. As reported by Business Standard, this substantial revenue growth demonstrates the company's strong market performance and operational efficiency during the quarter. The growth was driven by new market authorisations for oncology products, robust demand across geographies, and steady execution of key business initiatives, as highlighted in the latest earnings announcement.
EBITDA rose 67% YoY to ₹21.25 crore in Q1 FY2026, compared with ₹12.70 crore in Q1 FY2026, while the EBITDA margin improved to 29% from 24% a year ago. According to the latest financial data, this margin expansion indicates enhanced operational efficiency and better cost management during the quarter. The company's operating profit margin (OPM) improved to 29.12% in the June 2026 quarter, compared to 24.10% in the corresponding quarter of the previous year.
Profit Before Depreciation and Tax (PBDT) rose 93% to ₹21.12 crore in Q1 FY2026, significantly higher than ₹10.96 crore in the previous year's corresponding quarter. As reported by Business Standard, Profit Before Tax (PBT) increased by 171% to ₹14.58 crore from ₹5.38 crore in Q1 FY2025, reflecting the company's strong operational performance across all profitability metrics. The latest results show net profit surging 120% YoY to ₹10.28 crore from ₹4.67 crore in the year-ago period.
Sakar Healthcare share price opened at ₹817.45 apiece today, compared to the previous close of ₹802.20, and touched an intraday high of ₹833.90 on July 27. The stock has delivered multibagger returns of 101% on a year-to-date basis and 125.56% in a year, with 213% gains in three years and 354% gains in five years. According to latest market data, Sakar Healthcare has demonstrated consistent growth with a market capitalization of ₹1,841 crore, representing a 125% increase over the past year. The company maintains strong operational metrics with revenue of ₹252 crore and profit of ₹30.5 crore, while trading at 5.67 times its book value. The pharmaceutical manufacturer operates across over 50 countries with 292 registered products and partners with 70+ overseas distributors.
